Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Can non-clinical repolarization assays predict the results of clinical thorough QT studies? Results from a research consortium.

Park E, Gintant GA, Bi D, Kozeli D, Pettit SD, Pierson JB, Skinner M, Willard J, Wisialowski T, Koerner J, Valentin JP.

Br J Pharmacol. 2018 Feb;175(4):606-617. doi: 10.1111/bph.14101. Epub 2018 Jan 15.

2.

Enhancing quality of life as a goal for anticancer therapeutics.

Pettit SD, Lipshultz SE, Cleeland CS, Roberts S, Davis M, Berridge BR, Kirch RA.

Sci Transl Med. 2016 Jun 22;8(344):344ed9. doi: 10.1126/scitranslmed.aag0382.

PMID:
27334258
3.

From silos to multilingual science.

Pettit SD.

Sci Transl Med. 2014 Feb 12;6(223):223ed3. doi: 10.1126/scitranslmed.3008386. No abstract available.

4.

A public-private consortium advances cardiac safety evaluation: achievements of the HESI Cardiac Safety Technical Committee.

Pierson JB, Berridge BR, Brooks MB, Dreher K, Koerner J, Schultze AE, Sarazan RD, Valentin JP, Vargas HM, Pettit SD.

J Pharmacol Toxicol Methods. 2013 Jul-Aug;68(1):7-12. doi: 10.1016/j.vascn.2013.03.008. Epub 2013 Apr 6.

5.

Integrated and translational nonclinical in vivo cardiovascular risk assessment: gaps and opportunities.

Berridge BR, Hoffmann P, Turk JR, Sellke F, Gintant G, Hirkaler G, Dreher K, Schultze AE, Walker D, Edmunds N, Halpern W, Falls J, Sanders M, Pettit SD.

Regul Toxicol Pharmacol. 2013 Feb;65(1):38-46. doi: 10.1016/j.yrtph.2012.09.007. Epub 2012 Oct 5.

PMID:
23044254
6.

Current practices in preclinical drug development: gaps in hemostasis testing to assess risk of thromboembolic injury.

Schultze AE, Walker DB, Turk JR, Tarrant JM, Brooks MB, Pettit SD.

Toxicol Pathol. 2013;41(3):445-53. doi: 10.1177/0192623312460924. Epub 2012 Sep 18.

PMID:
22991386
7.

Human and environmental health challenges for the next decade (2010–2020).

Bonnefoi MS, Belanger SE, Devlin DJ, Doerrer NG, Embry MR, Fukushima S, Harpur ES, Hines RN, Holsapple MP, Kim JH, MacDonald JS, O'Lone R, Pettit SD, Stevens JL, Takei AS, Tinkle SS, van der Laan JW.

Crit Rev Toxicol. 2010 Nov;40(10):893-911. doi: 10.3109/10408444.2010.506640. Review.

PMID:
20854192
8.

What do we need to know prior to thinking about incorporating an epigenetic evaluation into safety assessments?

Goodman JI, Augustine KA, Cunnningham ML, Dixon D, Dragan YP, Falls JG, Rasoulpour RJ, Sills RC, Storer RD, Wolf DC, Pettit SD.

Toxicol Sci. 2010 Aug;116(2):375-81. doi: 10.1093/toxsci/kfq133. Epub 2010 Apr 29.

PMID:
20430866
9.

A call for more integrated cardiovascular safety assessment.

Pettit SD, Berridge B, Sarazan RD.

J Pharmacol Toxicol Methods. 2010 Jan-Feb;61(1):1-2. doi: 10.1016/j.vascn.2009.08.001. Epub 2009 Aug 23.

PMID:
19706331
10.

Current challenges in the evaluation of cardiac safety during drug development: translational medicine meets the Critical Path Initiative.

Piccini JP, Whellan DJ, Berridge BR, Finkle JK, Pettit SD, Stockbridge N, Valentin JP, Vargas HM, Krucoff MW; CSRC/HESI Writing Group.

Am Heart J. 2009 Sep;158(3):317-26. doi: 10.1016/j.ahj.2009.06.007. Epub 2009 Jul 23.

PMID:
19699852
11.

A HESI consortium approach to assess the human predictive value of non-clinical repolarization assays.

Trepakova ES, Koerner J, Pettit SD, Valentin JP; HESI Pro-Arrhythmia Committee.

J Pharmacol Toxicol Methods. 2009 Jul-Aug;60(1):45-50. doi: 10.1016/j.vascn.2009.05.002. Epub 2009 May 9.

PMID:
19439186
12.

Proceedings of a workshop on DNA adducts: biological significance and applications to risk assessment Washington, DC, April 13-14, 2004.

Sander M, Cadet J, Casciano DA, Galloway SM, Marnett LJ, Novak RF, Pettit SD, Preston RJ, Skare JA, Williams GM, Van Houten B, Gollapudi BB.

Toxicol Appl Pharmacol. 2005 Oct 1;208(1):1-20.

PMID:
16164957
13.

Toxicogenomics in risk assessment: communicating the challenges.

Pettit SD.

Environ Health Perspect. 2004 Aug;112(12):A662. No abstract available.

14.

Database development in toxicogenomics: issues and efforts.

Mattes WB, Pettit SD, Sansone SA, Bushel PR, Waters MD.

Environ Health Perspect. 2004 Mar;112(4):495-505. Review.

15.

Overview on the application of transcription profiling using selected nephrotoxicants for toxicology assessment.

Kramer JA, Pettit SD, Amin RP, Bertram TA, Car B, Cunningham M, Curtiss SW, Davis JW, Kind C, Lawton M, Naciff JM, Oreffo V, Roman RJ, Sistare FD, Stevens J, Thompson K, Vickers AE, Wild S, Afshari CA.

Environ Health Perspect. 2004 Mar;112(4):460-4. Review.

16.

Overview of an interlaboratory collaboration on evaluating the effects of model hepatotoxicants on hepatic gene expression.

Ulrich RG, Rockett JC, Gibson GG, Pettit SD.

Environ Health Perspect. 2004 Mar;112(4):423-7.

17.

Toxicogenomics in risk assessment: an overview of an HESI collaborative research program.

Pennie W, Pettit SD, Lord PG.

Environ Health Perspect. 2004 Mar;112(4):417-9. Review.

18.

Supplemental Content

Loading ...
Support Center